LPI (LP Information)' newest research report, the “NASH Drug Pipeline Industry Forecast” looks at past sales and reviews total world NASH Drug Pipeline sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH Drug Pipeline sales for 2023 through 2029. With NASH Drug Pipeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NASH Drug Pipeline industry.
This Insight Report provides a comprehensive analysis of the global NASH Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH Drug Pipeline market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH Drug Pipeline.
The global NASH Drug Pipeline market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key NASH Drug Pipeline players cover Intercept, Genfit, Allergan, Madrigal, Immuron, Galectin, Gilead, 89bio Inc and ABIONYX Pharma SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of NASH Drug Pipeline market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
By Mechanism of Action
Protease Inhibitor
Immunomodulatory
Multiple Kinase Inhibitor
By Molecule Types
Small molecule
Stem Cell Therapy
Gene Therapy
By Route of Administration:
Inhalation
Intravenous
Oral
Subcutaneous
Segmentation by application
Clinical
Academic Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Intercept
Genfit
Allergan
Madrigal
Immuron
Galectin
Gilead
89bio Inc
ABIONYX Pharma SA
Abivax SA
Abliva AB
Acquist Therapeutics
AdAlta Ltd
Afimmune Biopharma Ltd
Zhejiang Doer Biologics Corp
Dicerna Pharmaceuticals Inc
ChemomAb Ltd
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Inc
Engitix Ltd
Heprotech Inc
Hinova Pharmaceuticals Inc
HK inno.N Corp
HotSpot Therapeutics Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global NASH Drug Pipeline market?
What factors are driving NASH Drug Pipeline market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NASH Drug Pipeline market opportunities vary by end market size?
How does NASH Drug Pipeline break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global NASH Drug Pipeline Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for NASH Drug Pipeline by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for NASH Drug Pipeline by Country/Region, 2018, 2022 & 2029 2.2 NASH Drug Pipeline Segment by Type 2.2.1 Protease Inhibitor 2.2.2 Immunomodulatory 2.2.3 Multiple Kinase Inhibitor 2.3 NASH Drug Pipeline Sales by Type 2.3.1 Global NASH Drug Pipeline Sales Market Share by Type (2018-2023) 2.3.2 Global NASH Drug Pipeline Revenue and Market Share by Type (2018-2023) 2.3.3 Global NASH Drug Pipeline Sale Price by Type (2018-2023) 2.4 NASH Drug Pipeline Segment by Application 2.4.1 Clinical 2.4.2 Academic Research 2.5 NASH Drug Pipeline Sales by Application 2.5.1 Global NASH Drug Pipeline Sale Market Share by Application (2018-2023) 2.5.2 Global NASH Drug Pipeline Revenue and Market Share by Application (2018-2023) 2.5.3 Global NASH Drug Pipeline Sale Price by Application (2018-2023) 3 Global NASH Drug Pipeline by Company 3.1 Global NASH Drug Pipeline Breakdown Data by Company 3.1.1 Global NASH Drug Pipeline Annual Sales by Company (2018-2023) 3.1.2 Global NASH Drug Pipeline Sales Market Share by Company (2018-2023) 3.2 Global NASH Drug Pipeline Annual Revenue by Company (2018-2023) 3.2.1 Global NASH Drug Pipeline Revenue by Company (2018-2023) 3.2.2 Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023) 3.3 Global NASH Drug Pipeline Sale Price by Company 3.4 Key Manufacturers NASH Drug Pipeline Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers NASH Drug Pipeline Product Location Distribution 3.4.2 Players NASH Drug Pipeline Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for NASH Drug Pipeline by Geographic Region 4.1 World Historic NASH Drug Pipeline Market Size by Geographic Region (2018-2023) 4.1.1 Global NASH Drug Pipeline Annual Sales by Geographic Region (2018-2023) 4.1.2 Global NASH Drug Pipeline Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic NASH Drug Pipeline Market Size by Country/Region (2018-2023) 4.2.1 Global NASH Drug Pipeline Annual Sales by Country/Region (2018-2023) 4.2.2 Global NASH Drug Pipeline Annual Revenue by Country/Region (2018-2023) 4.3 Americas NASH Drug Pipeline Sales Growth 4.4 APAC NASH Drug Pipeline Sales Growth 4.5 Europe NASH Drug Pipeline Sales Growth 4.6 Middle East & Africa NASH Drug Pipeline Sales Growth 5 Americas 5.1 Americas NASH Drug Pipeline Sales by Country 5.1.1 Americas NASH Drug Pipeline Sales by Country (2018-2023) 5.1.2 Americas NASH Drug Pipeline Revenue by Country (2018-2023) 5.2 Americas NASH Drug Pipeline Sales by Type 5.3 Americas NASH Drug Pipeline Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC NASH Drug Pipeline Sales by Region 6.1.1 APAC NASH Drug Pipeline Sales by Region (2018-2023) 6.1.2 APAC NASH Drug Pipeline Revenue by Region (2018-2023) 6.2 APAC NASH Drug Pipeline Sales by Type 6.3 APAC NASH Drug Pipeline Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe NASH Drug Pipeline by Country 7.1.1 Europe NASH Drug Pipeline Sales by Country (2018-2023) 7.1.2 Europe NASH Drug Pipeline Revenue by Country (2018-2023) 7.2 Europe NASH Drug Pipeline Sales by Type 7.3 Europe NASH Drug Pipeline Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa NASH Drug Pipeline by Country 8.1.1 Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023) 8.1.2 Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023) 8.2 Middle East & Africa NASH Drug Pipeline Sales by Type 8.3 Middle East & Africa NASH Drug Pipeline Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of NASH Drug Pipeline 10.3 Manufacturing Process Analysis of NASH Drug Pipeline 10.4 Industry Chain Structure of NASH Drug Pipeline 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 NASH Drug Pipeline Distributors 11.3 NASH Drug Pipeline Customer 12 World Forecast Review for NASH Drug Pipeline by Geographic Region 12.1 Global NASH Drug Pipeline Market Size Forecast by Region 12.1.1 Global NASH Drug Pipeline Forecast by Region (2024-2029) 12.1.2 Global NASH Drug Pipeline Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global NASH Drug Pipeline Forecast by Type 12.7 Global NASH Drug Pipeline Forecast by Application 13 Key Players Analysis 13.1 Intercept 13.1.1 Intercept Company Information 13.1.2 Intercept NASH Drug Pipeline Product Portfolios and Specifications 13.1.3 Intercept NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Intercept Main Business Overview 13.1.5 Intercept Latest Developments 13.2 Genfit 13.2.1 Genfit Company Information 13.2.2 Genfit NASH Drug Pipeline Product Portfolios and Specifications 13.2.3 Genfit NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Genfit Main Business Overview 13.2.5 Genfit Latest Developments 13.3 Allergan 13.3.1 Allergan Company Information 13.3.2 Allergan NASH Drug Pipeline Product Portfolios and Specifications 13.3.3 Allergan NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Allergan Main Business Overview 13.3.5 Allergan Latest Developments 13.4 Madrigal 13.4.1 Madrigal Company Information 13.4.2 Madrigal NASH Drug Pipeline Product Portfolios and Specifications 13.4.3 Madrigal NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Madrigal Main Business Overview 13.4.5 Madrigal Latest Developments 13.5 Immuron 13.5.1 Immuron Company Information 13.5.2 Immuron NASH Drug Pipeline Product Portfolios and Specifications 13.5.3 Immuron NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Immuron Main Business Overview 13.5.5 Immuron Latest Developments 13.6 Galectin 13.6.1 Galectin Company Information 13.6.2 Galectin NASH Drug Pipeline Product Portfolios and Specifications 13.6.3 Galectin NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Galectin Main Business Overview 13.6.5 Galectin Latest Developments 13.7 Gilead 13.7.1 Gilead Company Information 13.7.2 Gilead NASH Drug Pipeline Product Portfolios and Specifications 13.7.3 Gilead NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 Gilead Main Business Overview 13.7.5 Gilead Latest Developments 13.8 89bio Inc 13.8.1 89bio Inc Company Information 13.8.2 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications 13.8.3 89bio Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 89bio Inc Main Business Overview 13.8.5 89bio Inc Latest Developments 13.9 ABIONYX Pharma SA 13.9.1 ABIONYX Pharma SA Company Information 13.9.2 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications 13.9.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 ABIONYX Pharma SA Main Business Overview 13.9.5 ABIONYX Pharma SA Latest Developments 13.10 Abivax SA 13.10.1 Abivax SA Company Information 13.10.2 Abivax SA NASH Drug Pipeline Product Portfolios and Specifications 13.10.3 Abivax SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Abivax SA Main Business Overview 13.10.5 Abivax SA Latest Developments 13.11 Abliva AB 13.11.1 Abliva AB Company Information 13.11.2 Abliva AB NASH Drug Pipeline Product Portfolios and Specifications 13.11.3 Abliva AB NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Abliva AB Main Business Overview 13.11.5 Abliva AB Latest Developments 13.12 Acquist Therapeutics 13.12.1 Acquist Therapeutics Company Information 13.12.2 Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications 13.12.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Acquist Therapeutics Main Business Overview 13.12.5 Acquist Therapeutics Latest Developments 13.13 AdAlta Ltd 13.13.1 AdAlta Ltd Company Information 13.13.2 AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications 13.13.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 AdAlta Ltd Main Business Overview 13.13.5 AdAlta Ltd Latest Developments 13.14 Afimmune Biopharma Ltd 13.14.1 Afimmune Biopharma Ltd Company Information 13.14.2 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications 13.14.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.14.4 Afimmune Biopharma Ltd Main Business Overview 13.14.5 Afimmune Biopharma Ltd Latest Developments 13.15 Zhejiang Doer Biologics Corp 13.15.1 Zhejiang Doer Biologics Corp Company Information 13.15.2 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications 13.15.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.15.4 Zhejiang Doer Biologics Corp Main Business Overview 13.15.5 Zhejiang Doer Biologics Corp Latest Developments 13.16 Dicerna Pharmaceuticals Inc 13.16.1 Dicerna Pharmaceuticals Inc Company Information 13.16.2 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications 13.16.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.16.4 Dicerna Pharmaceuticals Inc Main Business Overview 13.16.5 Dicerna Pharmaceuticals Inc Latest Developments 13.17 ChemomAb Ltd 13.17.1 ChemomAb Ltd Company Information 13.17.2 ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications 13.17.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.17.4 ChemomAb Ltd Main Business Overview 13.17.5 ChemomAb Ltd Latest Developments 13.18 DURECT Corp 13.18.1 DURECT Corp Company Information 13.18.2 DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications 13.18.3 DURECT Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.18.4 DURECT Corp Main Business Overview 13.18.5 DURECT Corp Latest Developments 13.19 Eli Lilly and Co 13.19.1 Eli Lilly and Co Company Information 13.19.2 Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications 13.19.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.19.4 Eli Lilly and Co Main Business Overview 13.19.5 Eli Lilly and Co Latest Developments 13.20 Enanta Pharmaceuticals Inc 13.20.1 Enanta Pharmaceuticals Inc Company Information 13.20.2 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications 13.20.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.20.4 Enanta Pharmaceuticals Inc Main Business Overview 13.20.5 Enanta Pharmaceuticals Inc Latest Developments 13.21 EncuraGen Inc 13.21.1 EncuraGen Inc Company Information 13.21.2 EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications 13.21.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.21.4 EncuraGen Inc Main Business Overview 13.21.5 EncuraGen Inc Latest Developments 13.22 Engitix Ltd 13.22.1 Engitix Ltd Company Information 13.22.2 Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications 13.22.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.22.4 Engitix Ltd Main Business Overview 13.22.5 Engitix Ltd Latest Developments 13.23 Heprotech Inc 13.23.1 Heprotech Inc Company Information 13.23.2 Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications 13.23.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.23.4 Heprotech Inc Main Business Overview 13.23.5 Heprotech Inc Latest Developments 13.24 Hinova Pharmaceuticals Inc 13.24.1 Hinova Pharmaceuticals Inc Company Information 13.24.2 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications 13.24.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.24.4 Hinova Pharmaceuticals Inc Main Business Overview 13.24.5 Hinova Pharmaceuticals Inc Latest Developments 13.25 HK inno.N Corp 13.25.1 HK inno.N Corp Company Information 13.25.2 HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications 13.25.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.25.4 HK inno.N Corp Main Business Overview 13.25.5 HK inno.N Corp Latest Developments 13.26 HotSpot Therapeutics Inc 13.26.1 HotSpot Therapeutics Inc Company Information 13.26.2 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications 13.26.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023) 13.26.4 HotSpot Therapeutics Inc Main Business Overview 13.26.5 HotSpot Therapeutics Inc Latest Developments 14 Research Findings and Conclusion